| abstract |
The antibody combined with IL33R, it is characterised in that heavy chain variable domain includes SEQ ID NO:1 CDR3 areas, SEQ ID NO:2 CDR2 areas and SEQ ID NO:3 CDR1 areas, and it is characterized in that light-chain variable domain includes SEQ ID NO:4 CDR3 areas, SEQ ID NO:5 CDR2 areas and SEQ ID NO:6 CDR1 areas, or the antibody are the antibody variants of the chimeric antibody, humanized antibody or t cell epitope missing of the favorable property with treatment inflammatory disease. |